Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication
Implementation of inactivated polio vaccines (IPV) containing Sabin strains (sIPV) will further enable global polio eradication efforts by improving vaccine safety during use and containment during manufacturing. Moreover, sIPV-containing vaccines will lower costs and expand production capacity to f...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2022.2154100 |
| _version_ | 1797673108918763520 |
|---|---|
| author | Prashant Kumar Christopher Bird David Holland Sangeeta B. Joshi David B. Volkin |
| author_facet | Prashant Kumar Christopher Bird David Holland Sangeeta B. Joshi David B. Volkin |
| author_sort | Prashant Kumar |
| collection | DOAJ |
| description | Implementation of inactivated polio vaccines (IPV) containing Sabin strains (sIPV) will further enable global polio eradication efforts by improving vaccine safety during use and containment during manufacturing. Moreover, sIPV-containing vaccines will lower costs and expand production capacity to facilitate more widespread use in low- and middle-income countries (LMICs). This review focuses on the role of vaccine formulation in these efforts including traditional Salk IPV vaccines and new sIPV-containing dosage forms. The physicochemical properties and stability profiles of poliovirus antigens are described. Formulation approaches to lower costs include developing multidose and combination vaccine formats as well as improving storage stability. Formulation strategies for dose-sparing and enhanced mucosal immunity include employing adjuvants (e.g. aluminum-salt and newer adjuvants) and/or novel delivery systems (e.g. ID administration with microneedle patches). The potential for applying these low-cost formulation development strategies to other vaccines to further improve vaccine access and coverage in LMICs is also discussed. |
| first_indexed | 2024-03-11T21:39:44Z |
| format | Article |
| id | doaj.art-62ea5b6f2aeb4dde920e62169fbc236e |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:39:44Z |
| publishDate | 2022-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-62ea5b6f2aeb4dde920e62169fbc236e2023-09-26T13:25:46ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-12-0118710.1080/21645515.2022.21541002154100Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradicationPrashant Kumar0Christopher Bird1David Holland2Sangeeta B. Joshi3David B. Volkin4University of KansasUniversity of KansasUniversity of KansasUniversity of KansasUniversity of KansasImplementation of inactivated polio vaccines (IPV) containing Sabin strains (sIPV) will further enable global polio eradication efforts by improving vaccine safety during use and containment during manufacturing. Moreover, sIPV-containing vaccines will lower costs and expand production capacity to facilitate more widespread use in low- and middle-income countries (LMICs). This review focuses on the role of vaccine formulation in these efforts including traditional Salk IPV vaccines and new sIPV-containing dosage forms. The physicochemical properties and stability profiles of poliovirus antigens are described. Formulation approaches to lower costs include developing multidose and combination vaccine formats as well as improving storage stability. Formulation strategies for dose-sparing and enhanced mucosal immunity include employing adjuvants (e.g. aluminum-salt and newer adjuvants) and/or novel delivery systems (e.g. ID administration with microneedle patches). The potential for applying these low-cost formulation development strategies to other vaccines to further improve vaccine access and coverage in LMICs is also discussed.http://dx.doi.org/10.1080/21645515.2022.2154100inactivated polio vaccinecombination vaccinesformulationstabilityd-antigen elisadose-sparingadjuvantsvaccine delivery |
| spellingShingle | Prashant Kumar Christopher Bird David Holland Sangeeta B. Joshi David B. Volkin Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication Human Vaccines & Immunotherapeutics inactivated polio vaccine combination vaccines formulation stability d-antigen elisa dose-sparing adjuvants vaccine delivery |
| title | Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication |
| title_full | Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication |
| title_fullStr | Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication |
| title_full_unstemmed | Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication |
| title_short | Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication |
| title_sort | current and next generation formulation strategies for inactivated polio vaccines to lower costs increase coverage and facilitate polio eradication |
| topic | inactivated polio vaccine combination vaccines formulation stability d-antigen elisa dose-sparing adjuvants vaccine delivery |
| url | http://dx.doi.org/10.1080/21645515.2022.2154100 |
| work_keys_str_mv | AT prashantkumar currentandnextgenerationformulationstrategiesforinactivatedpoliovaccinestolowercostsincreasecoverageandfacilitatepolioeradication AT christopherbird currentandnextgenerationformulationstrategiesforinactivatedpoliovaccinestolowercostsincreasecoverageandfacilitatepolioeradication AT davidholland currentandnextgenerationformulationstrategiesforinactivatedpoliovaccinestolowercostsincreasecoverageandfacilitatepolioeradication AT sangeetabjoshi currentandnextgenerationformulationstrategiesforinactivatedpoliovaccinestolowercostsincreasecoverageandfacilitatepolioeradication AT davidbvolkin currentandnextgenerationformulationstrategiesforinactivatedpoliovaccinestolowercostsincreasecoverageandfacilitatepolioeradication |